Mike Doustdar took over at Novo Nordisk in August 2025, and he tells Brian Sozzi the obesity pill has had the biggest launch of any product he can think of apart from the Covid vaccine. It is on sale in eight countries and he expects more than twenty by early 2027.
He also sets out what happens when Ozempic and Wegovy lose patent protection early in the next decade. His answer is that no single drug replaces them. Four or five will have to.
And asked how a change of control in Washington changes his business, he says: nothing, and explains why.
Featuring
Mike Doustdar, President and Chief Executive Officer, Novo Nordisk
Full episode: https://www.youtube.com/watch?v=7XgMtFJCyBY
Timestamps
0:00 The launch he says only the Covid vaccine beat
1:39 What replaces Ozempic and Wegovy when the patents run out
3:09 Why he says no launch this big has happened before
4:55 Why he says obesity is not one condition
7:41 What the CVS split means for a drugmaker
9:02 How the election changes his business
#NovoNordisk #Ozempic #Wegovy #ObesityDrugs #SozziUnleashed #YahooFinance
==
AlphaSpace by Yahoo Finance: A Professional-Grade Investment Platform Built for Everyday Investors.
👉 https://finance.yahoo.com/about/promos/gold/alphaspace?ncid=100003571
